Mobile

A Randomised, Double-Blind Study Comparing the Safety and Efficacy of Etanercept with Sulphasalazine in Subjects with Ankylosing Spondylitis

Update Il y a 5 ans
Reference: EUCTR2005-001549-41

Woman and Man

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

To compare the efficacy of etanercept 50 mg once weekly with SSZ 3 g daily in the treatment of AS subjects over 16 weeks. The study hypothesis is that etanercept 50 mg once weekly will demonstrate superior clinical efficacy, as determined by the proportion of responders achieving a 20% improvement on the Assessment of AS (ASAS) response criteria (ASAS 20; Attachment 2) at 16 weeks, compared with SSZ 3 g daily in the treatment of AS subjects.

Inclusion criteria

  • Subjects with Ankylosing Spondylitis (AS)

Links